Boehringer Ingelheim GmbH Release: FDA and FDA Reaffirm Important Health Benefits and Safety of Pradaxa® (dabigatran etexilate) for Patients With Atrial Fibrillation
11/5/2012 9:55:43 AM
More...
|
FDA: No Increased Bleeding Risk for Boehringer Ingelheim GmbH's Pradaxa
11/2/2012 2:47:05 PM
More...
|
Wealth of Worldwide Evidence on Boehringer Ingelheim GmbH's Pradaxa® Including First Clinical Data on Long-Term Efficacy and Safety of a Novel Oral Anticoagulant to be Presented at American Heart Association Scientific Sessions
10/31/2012 8:26:16 AM
More...
|
Boehringer Ingelheim GmbH Release: Asian Populations With Atrial Fibrillation (AF) Benefit From Better Stroke Prevention With Pradaxa® (dabigatran etexilate) Compared to Warfarin
9/12/2012 10:20:42 AM
More...
|
Boehringer Ingelheim GmbH Release: AF Patients Who Require Surgery Benefit From a Shorter Treatment Interruption on Dabigatran Etexilate (Pradaxa®) Compared to Warfarin
6/18/2012 10:21:41 AM
More...
|
Sustained Viral Response Achieved in 83% of Hepatitis C Infected Patients with New HCV Protease Inhibitor from Boehringer Ingelheim GmbH
4/1/2011 9:22:57 AM
More...
|
Boehringer Ingelheim GmbH's Drug Lowers Bleeding Risk in Those Who Had Stroke
11/8/2010 7:55:01 AM
More...
|
Boehringer Ingelheim GmbH Release: PRADAX(TM) (Dabigatran Etexilate) Gains Approval in Canada for Stroke Prevention in Atrial Fibrillation
10/27/2010 11:52:45 AM
More...
|
Boehringer Ingelheim GmbH's Dabigatran: The Case of the Missing 110-mg Dose, Brigham and Women's Hospital Study
10/22/2010 6:29:34 AM
More...
|
Boehringer Ingelheim GmbH Ends Female Desire Drug Flibanserin Development After FDA's Safety Query
10/8/2010 7:45:59 AM
More...
|
|